Eslicarbazepine Acate Granulation for Tablet Flowability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Eslicarbazepine acetate exhibits poor flowability and compressibility due to its low bulk density, making it difficult to handle and formulate into effective tablets, especially on an industrial scale, and existing methods like direct compression face challenges with binding and dissolution.
Innovation Solution
A pharmaceutical composition comprising eslicarbazepine acetate in combination with povidone and croscarmellose sodium, where part of the binder is mixed with the drug as a powder and the remaining part is dissolved in the granulation liquid, using a wet granulation process to improve flowability and compressibility, and including magnesium stearate as a lubricant to enhance tablet formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eslicarbazepine acetate is used as the active ingredient, then pharmacological activity is achieved, but poor flowability and compressibility occur due to low bulk density
Solution Approach 1:
The bulk density of eslicarbazepine acetate is changed from low (poor flowability) to high (improved flowability) through the granulation process. The patent applies wet granulation to transform the physical parameters of the API, converting it from a free-flowing powder with low bulk density to granules with high bulk density (0.6-1.4 g/mL), thereby resolving the contradiction between maintaining pharmacological activity and improving flowability/compressibility for tablet formulation.
2Device complexity
If direct compression method is used, then formulation process is simplified, but binding and dissolution problems occur
Solution Approach 1:
Instead of directly compressing the API powder, the patent performs preliminary granulation to pre-form the API into granules with improved physical properties. This preliminary action of granulation prepares the material in advance with better flowability, compressibility, and dissolution characteristics, eliminating the need for direct compression and its associated binding problems.
3Ease of operation
If wet granulation process is applied, then flowability and compressibility are improved, but process complexity increases
Solution Approach 1:
The patent changes the physical state and parameters of the API through wet granulation, transforming low bulk density powder into high bulk density granules. This parameter change approach systematically improves flowability and compressibility while managing process complexity through controlled granulation conditions.
4Productivity
If bulk density is increased through granulation, then tablet production efficiency is improved, but dissolution properties may be affected
Solution Approach 1:
The patent optimizes granulation parameters to achieve a balance between bulk density increase (for improved productivity) and dissolution maintenance. By controlling granulation conditions and selecting appropriate excipients, the process increases bulk density to 0.6-1.4 g/mL while preserving dissolution properties through proper granule structure formation.
Data Source
AI summary
A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.